Skip to content

Insurance dropped your GLP-1 coverage? What to do next

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

If your plan stopped paying for Wegovy, Zepbound or another GLP-1, start by getting the reason in writing, because a dropped benefit, a formulary switch and a new approval rule each call for a different response. Then use your appeal or exception rights if they fit, and line up a cash price before your last refill runs out.

Step 1: find out what actually changed

Call the member number on your card and ask for the denial reason and the plan rule behind it. It will usually be one of three things.

The weight-loss benefit was removed. Employers decide this. Aetna, for example, tells employers they can include or exclude GLP-1 coverage for weight management [1]. Most people with job-based coverage are in self-funded plans, where the employer pays claims from its own funds [2]; KFF counts 67% of covered workers in such plans [3]. Premera says plainly that if a group does not choose weight-loss drug coverage, GLP-1s for obesity are not covered [4]. If this is what happened, your HR or benefits office is the one that decided.

The drug or its form changed. A plan can move you from one product to another. Blue Shield of California moved many members from the Zepbound single-dose pen to the KwikPen as of July 1, 2026 [7], with a new prescription but no new prior authorization for people already approved [8]. Blue Cross and Blue Shield of Illinois went the other way and excluded the Zepbound KwikPen [9].

A new approval rule. You may still have the benefit but no longer meet the plan’s prior authorization or renewal criteria. For renewal rules, see what renewal requires when your BMI has dropped.

One warning: an approval does not override an exclusion. BlueCross BlueShield of South Carolina notes that prior authorization approval does not guarantee payment if the member’s plan excludes the drug or use [5].

Changes insurers have posted

Plan What changed When
Blue Shield of California large group Weight-loss drug coverage now varies by employer [6] 2026
Blue Shield of California Zepbound single-dose pen members moved to the KwikPen [7] 2026
Blue Cross and Blue Shield of Illinois Zepbound KwikPen excluded [9] 2026
UnitedHealthcare Community Plan of Massachusetts (Medicaid) No longer covers drugs to treat weight loss and obesity [10] 2026
Rhode Island Medicaid Stops covering certain GLP-1s prescribed solely for weight loss [11] 2026
TRICARE (other than Prime and Select) Weight-loss drug coverage ended [12] 2025

For what your own insurer publishes, see GLP-1 coverage by insurer. If you are on Medicaid, see Medicaid by state.

Step 2: use your appeal and exception rights

Appeal. HealthCare.gov says that if your plan refuses to pay a claim or ends your coverage, you have the right to appeal and have the decision reviewed by a third party [13]. File the internal appeal within 180 days of the denial notice [14]. For care you have not received yet, the plan must finish that appeal within 30 days [15].

External review. If the plan upholds its denial, you can ask for an independent reviewer with no tie to the plan [16]. The written request is due within 4 months of the final denial [17], and a standard review is decided within 45 days [18]. In urgent cases you can request it before finishing internal appeals [19]. Any fee is capped at $25 [20].

Exception. An exception is a request for the plan to cover a drug that is not on its list, or to waive a coverage rule [21]. Some plans say outright that this path exists for weight-loss GLP-1s. FEP Blue, for federal employees, says an excluded weight-loss GLP-1 can still be obtained if your provider files a formulary exception [22]. Ambetter says your provider can request a non-formulary exception the same way as a prior authorization [23]. Your prescriber files it; the strongest ones quote the plan’s own criteria and attach your records.

These rules come from federal consumer pages, and your plan’s own letters are the best guide to its steps; the final decision must tell you how to ask for an external review [29]. The prior authorization guide covers the paperwork side.

Step 3: price a cash route now

Appeals take weeks, and medicine runs out on a fixed day. Both makers sell directly to people paying cash:

  • Wegovy pill: $149 for the starting bottle, and $299 at the 25 mg maintenance dose [24].
  • Wegovy injection: $349 a month at standard doses, $399 for Wegovy HD [25].
  • Zepbound vials or KwikPen: from $299 at 2.5 mg [26] to $449 at the top doses if you refill within 45 days [27].
  • On Medicare with Part D: the Medicare GLP-1 Bridge is $50 for a one-month supply if you qualify [28]; see the Bridge page.

Every cash option is compared on GLP-1 prices without insurance. Before switching medicine or dose to fit a price, talk to your prescriber.

Sources

  1. You can choose to customize your benefits to include or exclude GLP-1 drug coverage for weight management. aetna.com, read Sep 27, 2026.
  2. Many firms – particularly larger firms – have self-funded health plans, which means that they pay for the health services of enrollees directly from their own funds rather than through the purchase of health insurance. kff.org, read Sep 27, 2026.
  3. Sixty-seven percent of covered workers, including 27% of covered workers at firms with 10 to 199 workers and 80% at larger firms, are enrolled in plans that are self-funded. kff.org, read Sep 27, 2026.
  4. If a group does not elect weight‑loss drug coverage, GLP‑1s for obesity are not covered. producernews.premera.com, read Sep 27, 2026.
  5. Prior authorization approval does not guarantee payment if a member's benefit plan excludes coverage for the requested medication or indication. southcarolinablues.com, read Sep 27, 2026.
  6. As of January 1, 2026, weight loss drug coverage will vary for Blue Shield large group commercial health plans. blueshieldca.com, read Sep 27, 2026.
  7. requiring fully insured commercial HMO and PPO and select ASO members to transition from the single-dose auto-injector to the multi-dose Zepbound KwikPen®, effective July 1, 2026. blueshieldca.com, read Sep 27, 2026.
  8. Members will need a new prescription for the KwikPen version, including a prescription for pen needles, though no new prior authorization is required for those with existing approval. blueshieldca.com, read Sep 27, 2026.
  9. Zepbound Kwikpen, which is available only through direct‑to‑consumer pathways, has been excluded from coverage. bcbsil.com, read Sep 27, 2026.
  10. Beginning July 1, 2026, to comply with MassHealth, we’ll no longer cover prescription drugs used for the treatment of weight loss and obesity. uhcprovider.com, read Sep 27, 2026.
  11. beginning October 1, 2026, Rhode Island Medicaid will no longer cover certain GLP-1 receptor agonists when they are prescribed solely for weight loss. uhcprovider.com, read Sep 27, 2026.
  12. As of August 31, 2025, coverage for weight loss medications will no longer be available for non-TRICARE Prime and non-TRICARE Select beneficiaries. militaryrx.express-scripts.com, read Sep 27, 2026.
  13. If your health plan refuses to pay a claim or ends your coverage, you have the right to appeal the decision and have it reviewed by a third party. healthcare.gov, read Sep 27, 2026.
  14. You must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied. healthcare.gov, read Sep 27, 2026.
  15. Your internal appeal must be completed within 30 days if your appeal is for a service you haven’t received yet. healthcare.gov, read Sep 27, 2026.
  16. A review of a plan's decision to deny coverage for or payment of a service by an independent third-party not related to the plan. If the plan denies an appeal, an external review can be requested. healthcare.gov, read Sep 27, 2026.
  17. You must file a written request for an external review within 4 months after the date you receive a notice or final determination from your insurer that your claim has been denied. healthcare.gov, read Sep 27, 2026.
  18. no later than 45 days after the request was received. healthcare.gov, read Sep 27, 2026.
  19. In urgent situations, you can request an external review even if you haven’t completed all of the health plan’s internal appeals processes. healthcare.gov, read Sep 27, 2026.
  20. If so, the charge can’t be more than $25 per external review. healthcare.gov, read Sep 27, 2026.
  21. An exception is when a drug plan decides to cover a drug that's not on its drug list, or to waive a coverage rule. medicare.gov, read Sep 27, 2026.
  22. Yes, you can still obtain a weight loss GLP-1 that is not covered or excluded. In order to do so, your healthcare provider must submit a formulary exception request on your behalf. fepblue.org, read Sep 27, 2026.
  23. If your drug is not covered by our formulary, your provider can request a non-formulary exception request. ambetterhealth.com, read Sep 27, 2026.
  24. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg, and $299 per month for 9 mg and 25 mg. One month defined as 1 bottle of 30 tablets. novocare.com, read Sep 27, 2026.
  25. then $349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg, and $399 per month for Wegovy® HD (semaglutide) injection 7.2 mg. novocare.com, read Sep 27, 2026.
  26. 2.5 mg/0.6 mL (starting dosage) Self-pay price: Starting at $299/month* lilly.com, read Sep 27, 2026.
  27. 15 mg/0.6 mL Self-pay price: Starting at $449/month* when you refill within 45 days lilly.com, read Sep 27, 2026.
  28. You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug). medicare.gov, read Sep 27, 2026.
  29. The insurance company’s final determination must tell you how to ask for an external review. healthcare.gov, read Sep 27, 2026.